

At page 7, line 33, delete "Panel A" and substitute therefor --Figure 4A--.

At page 7, line 35, delete "Panel B" and substitute therefor --Figure 4B--.

At page 8, line 2, delete ;"Panel C" and substitute therefor --Figure 4C--.

At page 11, lines 14 and 15 and page 12, line 31, delete "Rockville, MD" and
substitute therefor --10801 University Boulevard, Manassas, VA 20110-2209--.

B2
In the claims:

In claim 61, last line, before "protein" insert -- a--.

B3
62. (amended) The method of immunizing according to claim 61 wherein the
[group A] polysaccharide has a molecular weight of about 10 Kd.

B4
67. (amended) The method of immunizing according to claim 66 wherein the
protein [of the polysaccharide-protein conjugate] is tetanus toxoid.

In claim 68, first line, before "polysaccharide" insert -- the --.

REMARKS

Claims 61-79 are pending in the application. Claims 73-79 have been withdrawn by the Examiner. Claims 61-72 are presented for examination on the merits.

The amendments to the specification and claims do not add new matter.

Applicants believe that the amendments are fully responsive to the Examiner's objections provided in the sections of the action entitled "Abstract," "Specification-Informalities," and "Objection(s) to Claims."

The Examiner notes that the specification makes reference, at page 11, lines 12-15, to a group A variant streptococcus and suggests that the application be amended to recite a corresponding accession number. Applicants do not believe it is necessary to amend the